Incyte Corporation (INCY)
NASDAQ: INCY · Real-Time Price · USD
97.34
+0.24 (0.25%)
At close: May 27, 2026, 4:00 PM EDT
95.45
-1.89 (-1.94%)
After-hours: May 27, 2026, 7:53 PM EDT
Incyte Revenue
Incyte had revenue of $1.27B in the quarter ending March 31, 2026, with 20.87% growth. This brings the company's revenue in the last twelve months to $5.36B, up 21.48% year-over-year. In the year 2025, Incyte had annual revenue of $5.14B with 21.22% growth.
Revenue (ttm)
$5.36B
Revenue Growth
+21.48%
P/S Ratio
3.63
Revenue / Employee
$1,885,028
Employees
2,844
Market Cap
19.45B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.14B | 900.02M | 21.22% |
| Dec 31, 2024 | 4.24B | 545.57M | 14.76% |
| Dec 31, 2023 | 3.70B | 301.01M | 8.87% |
| Dec 31, 2022 | 3.39B | 408.37M | 13.67% |
| Dec 31, 2021 | 2.99B | 319.57M | 11.98% |
| Dec 31, 2020 | 2.67B | 507.94M | 23.53% |
| Dec 31, 2019 | 2.16B | 276.88M | 14.71% |
| Dec 31, 2018 | 1.88B | 345.66M | 22.50% |
| Dec 31, 2017 | 1.54B | 430.50M | 38.93% |
| Dec 31, 2016 | 1.11B | 351.97M | 46.70% |
| Dec 31, 2015 | 753.75M | 242.26M | 47.36% |
| Dec 31, 2014 | 511.50M | 508.45M | 16,696.71% |
| Dec 31, 2013 | 3.05M | -294.01M | -98.97% |
| Dec 31, 2012 | 297.06M | 202.60M | 214.50% |
| Dec 31, 2011 | 94.46M | -75.42M | -44.40% |
| Dec 31, 2010 | 169.88M | 160.61M | 1,733.55% |
| Dec 31, 2009 | 9.27M | 5.35M | 136.41% |
| Dec 31, 2008 | 3.92M | -30.52M | -88.62% |
| Dec 31, 2007 | 34.44M | 6.80M | 24.59% |
| Dec 31, 2006 | 27.64M | 19.80M | 252.32% |
| Dec 31, 2005 | 7.85M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jazz Pharmaceuticals | 4.44B |
| Genmab | 3.90B |
| BioNTech SE | 3.23B |
| Exelixis | 2.38B |
| Moderna | 2.23B |
| Ionis Pharmaceuticals | 1.06B |
| Ascendis Pharma | 998.25M |
| Insmed | 819.56M |
INCY News
- 15 hours ago - Incyte Proxy statement: Proxy filing - Filings
- 1 day ago - Incyte to Present at the Goldman Sachs 47th Annual Global Healthcare Conference - Business Wire
- 2 days ago - Incyte Sets Mid-Year Phase 3 Trial for CALR Antibody 989 as Pipeline Updates Roll Out - MarketBeat
- 6 days ago - Bernstein starts Incyte at MarketPerform, sees no clear path for revenue rebound - TheFly
- 6 days ago - Incyte initiated with a Market Perform at Bernstein - TheFly
- 7 days ago - Inside Incyte's $120 Million AI For Drug Development Deal - Forbes
- 7 days ago - Incyte, Genesis Molecular AI announce expansion of collaboration - TheFly
- 7 days ago - Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery - Business Wire